VEGFA and hepatocellular carcinoma: The combination of bevacizumab (an anti-VEGF) plus atezolizumab (an anti-PD-L1) is the only immunotherapeutic approach used as a first-line treatment in HCC patients with portal invasion, extrahepatic spread, preserved liver function, and ECOG PS 0–2 [127].